Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Market changes underway for China
June 2018
SHARING OPTIONS:

BEIJING—As of May 1, the import tariff for all “common drugs,” including anticancer drugs, alkaloids with anticancer effects and imported patented Chinese medicines, will be reduced to zero as part of an effort to secure China as a leading destination for clinical drug trials. A “large reduction” will also be made to the value-added tax applied to the production and import of anticancer drugs, and the clinical trial application will be changed from the standard approval process to the default approval, meaning that imported chemical drugs can be cleared on the examination results of enterprises rather than compulsory batch custom examinations.
 
Regarding these and related changes and new policies, Philip Gregory, managing director of contract research organization George Clinical in China, said: “This is an exciting time to run a clinical trial in China. There is a remarkable push by the Government to make sure that China is at the forefront of R&D globally.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.